Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.
2.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
3.

Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes.

Shand B, Scott R, Connolly S, Clarke R, Baker J, Elder P, Frampton C, Yeo J.

Diabetes Obes Metab. 2007 Jul;9(4):540-7.

PMID:
17587396
4.

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.

Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.

Drugs Aging. 2004;21(4):259-71.

PMID:
15012171
6.
7.
9.

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.

Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M; GLAC Study Group.

Diabet Med. 2004 Aug;21(8):859-66.

PMID:
15270789
10.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
11.

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.

Metabolism. 2008 Nov;57(11):1552-7. doi: 10.1016/j.metabol.2008.06.010.

PMID:
18940393
12.
13.
14.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
15.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

Diabetes Care. 2004 Jan;27(1):141-7.

PMID:
14693980
16.

Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.

Chogtu B, Singh NP, Chawla S, Gupta U.

Singapore Med J. 2009 Apr;50(4):395-9.

17.

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.

Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; QUARTET Study Group.

Diabet Med. 2005 Apr;22(4):399-405.

PMID:
15787663
18.

Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.

Miyazaki Y, DeFronzo RA.

Diabetes Obes Metab. 2008 Dec;10(12):1204-11. doi: 10.1111/j.1463-1326.2008.00880.x. Epub 2008 May 12.

PMID:
18476983
19.

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S.

Diabetes Obes Metab. 2007 Mar;9(2):175-85.

PMID:
17300593
20.

Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.

Davidson JA, Perez A, Zhang J; Pioglitazone 343 Study Group.

Diabetes Obes Metab. 2006 Mar;8(2):164-74.

PMID:
16448520

Supplemental Content

Support Center